InMed Pharmaceuticals Inc. (IMLFF) A Leader in Cannabinoid Biosynthesis — CFN Media

InMed Pharma: A Leader in Cannabinoid Biosynthesis — CFN Media InMed Pharmaceuticals CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. ( CSE :IN ) ( CNSX : IN ) (IN.CN) ( OTCQB : IMLFF ) is leveraging biosynthesis to solve a major problem in the medical cannabis
Complete Reading

InMed Announces Publication in European Journal of Pain InMed Pharmaceuticals, Inc PRESS RELEASE . (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of company-sponsored research in the European Journal of Pain.  The article, titled “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization
Complete Reading

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use Buz Investors NetworkNewsWire Announces PublicationNetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF), an NNW client that specializes in developing novel therapies through the research and development into the
Complete Reading

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference Buz Investors InMed Pharmaceuticals  (“InMed”) (CSE: IN; OTCQB: IMLFF) announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California.
Complete Reading

Create Account



Log In Your Account